Plus Therapeutics (FRA:XMP1) Valuation Rank


FRA:XMP1 Plus Therapeutics Inc FRA:XMP1
22 GF Score
Price €3.38
! 2 Warning Signs
View Full Analysis

What is Plus Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Plus Therapeutics Valuation Rank Related Terms

FRA:XMP1
22GF Score
Plus Therapeutics Inc FRA:XMP1
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Plus Therapeutics Business Description

Other Exchanges PSTV:USA
Address 6420 Levit Green Boulevard, Suite 210, Houston, TX, USA, 77021
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
22GF Score

Get the complete analysis for FRA:XMP1

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.38
Price